These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

601 related items for PubMed ID: 27710160

  • 1. Treatment of Nonalcoholic Fatty Liver Disease with Long-Chain n-3 Polyunsaturated Fatty Acids in Humans.
    Kelley NS.
    Metab Syndr Relat Disord; 2016 Nov; 14(9):417-430. PubMed ID: 27710160
    [Abstract] [Full Text] [Related]

  • 2. Different Effects of Eicosapentaenoic and Docosahexaenoic Acids on Atherogenic High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice.
    Suzuki-Kemuriyama N, Matsuzaka T, Kuba M, Ohno H, Han SI, Takeuchi Y, Isaka M, Kobayashi K, Iwasaki H, Yatoh S, Suzuki H, Miyajima K, Nakae D, Yahagi N, Nakagawa Y, Sone H, Yamada N, Shimano H.
    PLoS One; 2016 Nov; 11(6):e0157580. PubMed ID: 27333187
    [Abstract] [Full Text] [Related]

  • 3. Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected].
    Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Calder PC, Byrne CD, WELCOME Trial Investigators.
    Contemp Clin Trials; 2014 Mar; 37(2):301-11. PubMed ID: 24556343
    [Abstract] [Full Text] [Related]

  • 4. Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial.
    Nogueira MA, Oliveira CP, Ferreira Alves VA, Stefano JT, Rodrigues LS, Torrinhas RS, Cogliati B, Barbeiro H, Carrilho FJ, Waitzberg DL.
    Clin Nutr; 2016 Jun; 35(3):578-86. PubMed ID: 26047766
    [Abstract] [Full Text] [Related]

  • 5. n-3 polyunsaturated fatty acids in phospholipid or triacylglycerol form attenuate nonalcoholic fatty liver disease via mediating cannabinoid receptor 1/adiponectin/ceramide pathway.
    Chen YF, Fan ZK, Gao X, Zhou F, Guo XF, Sinclair AJ, Li D.
    J Nutr Biochem; 2024 Jan; 123():109484. PubMed ID: 37866428
    [Abstract] [Full Text] [Related]

  • 6. Targeting n-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease.
    Valenzuela R, Ortiz M, Hernández-Rodas MC, Echeverría F, Videla LA.
    Curr Med Chem; 2020 Jan; 27(31):5250-5272. PubMed ID: 30968772
    [Abstract] [Full Text] [Related]

  • 7. Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action.
    Scorletti E, Byrne CD.
    Mol Aspects Med; 2018 Dec; 64():135-146. PubMed ID: 29544992
    [Abstract] [Full Text] [Related]

  • 8. Anti-steatotic effects of an n-3 LCPUFA and extra virgin olive oil mixture in the liver of mice subjected to high-fat diet.
    Valenzuela R, Espinosa A, Llanos P, Hernandez-Rodas MC, Barrera C, Vergara D, Romero N, Pérez F, Ruz M, Videla LA.
    Food Funct; 2016 Jan; 7(1):140-50. PubMed ID: 26471014
    [Abstract] [Full Text] [Related]

  • 9. Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD.
    Pathil A, Liebisch G, Okun JG, Chamulitrat W, Schmitz G, Stremmel W.
    Eur J Clin Invest; 2015 Sep; 45(9):925-31. PubMed ID: 26108973
    [Abstract] [Full Text] [Related]

  • 10. Dietary DHA/EPA Ratio Changes Fatty Acid Composition and Attenuates Diet-Induced Accumulation of Lipid in the Liver of ApoE-/- Mice.
    Liu L, Hu Q, Wu H, Wang X, Gao C, Chen G, Yao P, Gong Z.
    Oxid Med Cell Longev; 2018 Sep; 2018():6256802. PubMed ID: 30538803
    [Abstract] [Full Text] [Related]

  • 11. Omega-3 fatty acids and nonalcoholic fatty liver disease in adults and children: where do we stand?
    Spooner MH, Jump DB.
    Curr Opin Clin Nutr Metab Care; 2019 Mar; 22(2):103-110. PubMed ID: 30601174
    [Abstract] [Full Text] [Related]

  • 12. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study.
    Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Hodson L, Moyses HE, Calder PC, Byrne CD, WELCOME Study.
    Hepatology; 2014 Oct; 60(4):1211-21. PubMed ID: 25043514
    [Abstract] [Full Text] [Related]

  • 13. Hydroxytyrosol prevents reduction in liver activity of Δ-5 and Δ-6 desaturases, oxidative stress, and depletion in long chain polyunsaturated fatty acid content in different tissues of high-fat diet fed mice.
    Valenzuela R, Echeverria F, Ortiz M, Rincón-Cervera MÁ, Espinosa A, Hernandez-Rodas MC, Illesca P, Valenzuela A, Videla LA.
    Lipids Health Dis; 2017 Apr 11; 16(1):64. PubMed ID: 28395666
    [Abstract] [Full Text] [Related]

  • 14. Docosahexaenoic acid attenuates hepatic inflammation, oxidative stress, and fibrosis without decreasing hepatosteatosis in a Ldlr(-/-) mouse model of western diet-induced nonalcoholic steatohepatitis.
    Depner CM, Philbrick KA, Jump DB.
    J Nutr; 2013 Mar 11; 143(3):315-23. PubMed ID: 23303872
    [Abstract] [Full Text] [Related]

  • 15. Nonalcoholic fatty liver disease: Roles of the gut and the liver and metabolic modulation by some dietary factors and especially long-chain n-3 PUFA.
    Delarue J, Lallès JP.
    Mol Nutr Food Res; 2016 Jan 11; 60(1):147-59. PubMed ID: 26300318
    [Abstract] [Full Text] [Related]

  • 16. Protective effects of various ratios of DHA/EPA supplementation on high-fat diet-induced liver damage in mice.
    Shang T, Liu L, Zhou J, Zhang M, Hu Q, Fang M, Wu Y, Yao P, Gong Z.
    Lipids Health Dis; 2017 Mar 29; 16(1):65. PubMed ID: 28356106
    [Abstract] [Full Text] [Related]

  • 17. Potential for dietary ω-3 fatty acids to prevent nonalcoholic fatty liver disease and reduce the risk of primary liver cancer.
    Jump DB, Depner CM, Tripathy S, Lytle KA.
    Adv Nutr; 2015 Nov 29; 6(6):694-702. PubMed ID: 26567194
    [Abstract] [Full Text] [Related]

  • 18. Effects of Omega-3 Polyunsaturated Fatty Acid Supplementation on Bone Turnover in Older Women.
    Dong H, Hutchins-Wiese H, Kleppinger A, Annis K, Liva E, Lammi-Keefe C, Durham H, Feinn R, Kenny AM.
    Int J Vitam Nutr Res; 2014 Nov 29; 84(3-4):124-32. PubMed ID: 26098476
    [Abstract] [Full Text] [Related]

  • 19. Role of Omega-3 fatty acids eicosapentaenoic (EPA) and docosahexaenoic (DHA) as modulatory and anti-inflammatory agents in noncommunicable diet-related diseases - Reports from the last 10 years.
    Banaszak M, Dobrzyńska M, Kawka A, Górna I, Woźniak D, Przysławski J, Drzymała-Czyż S.
    Clin Nutr ESPEN; 2024 Oct 29; 63():240-258. PubMed ID: 38980796
    [Abstract] [Full Text] [Related]

  • 20. Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression.
    Bhatia L, Scorletti E, Curzen N, Clough GF, Calder PC, Byrne CD.
    Atherosclerosis; 2016 Mar 29; 246():13-20. PubMed ID: 26748347
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.